Condition: Malignant Pleural Mesothelioma · Sponsor: University Hospital, Antwerp
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.
This description comes directly from the study's public registry record.
Zwi N Berneman, MD, PhD · 0032 3 821 39 15 · zwi.berneman@uza.be
Barbara Stein, MSc · 0032 3 821 31 22 · Barbara.Stein@uza.be
Always discuss trial participation with your own doctor first.
| Antwerp University Hospital | Edegem, Antwerp, Belgium | Recruiting |
| AZ Maria Middelares | Ghent, Belgium | Recruiting |
| VITAZ | Sint-Niklaas, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05765084